<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/BE63C194-6B14-4150-9DF2-A18D0E1E465B" ns1:id="BE63C194-6B14-4150-9DF2-A18D0E1E465B"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/B1EA0B38-790A-41CA-908D-3EC1B182AEA0" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/FAC18624-2C4C-4115-8781-28A0D0EAC698" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/6B57D64D-182B-4847-8A8F-366E0669D013" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/FAC18624-2C4C-4115-8781-28A0D0EAC698" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2016-01-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/48281198-9425-428E-8969-7A82C8D2DBC8" ns1:rel="FUND" ns1:start="2014-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">102007</ns2:identifier></ns2:identifiers><ns2:title>Clinical Asssesment of Compact Gamma Camera: An advancement in cancer diagnosis</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>The project aims to address the recognised need for greater accuracy in Sentinel Lymph Node Biopsy (SLNB), the standard procedure for evaluating &amp;amp; diagnosing a range of cancers - notably breast cancer &amp;amp; melanoma, through the development &amp;amp; clinical testing of a unique Compact Gamma Camera (CGC). The device will not only improve SLNB accuracy (to ~99.5%) but also improve rates of healing (by tissue sparing &amp;amp; nerve damage prevention): this advancement in imaging for cancer diagnosis will be provided at a cost of 60% less than current best in class gamma cameras. The CGC has the potential to deliver healthcare savings of ~&amp;pound;650Mp.a. in the targeted EU &amp;amp; US markets. The project, led by Xstrahl (SME), will include clinical assessment of the CGC for SLN detection in both breast cancer &amp;amp; melanoma across 2 major centres where these cancers are treated &amp;amp; practice taught: University of Nottingham (UoN) &amp;amp; Netherlands Cancer Institute (NKI).</ns2:abstractText></ns2:project>